OCOYOACAC

Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)

Retrieved on: 
Thursday, June 17, 2021
Vaccination, Drugs, Vaccines, Medical specialties, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Sanofi, Influenza, Quadrivalent vaccine, Influenza A virus subtype H3N2

The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.

Key Points: 
  • The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.
  • Fluzone High-Dose Quadrivalent is a vaccine indicated for prevention of influenza disease caused by influenza A and B strains contained in the vaccine.
  • Vaccination with Fluzone High-Dose Quadrivalent may not protect all people who receive the vaccine.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.|

Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine

Retrieved on: 
Wednesday, March 31, 2021
Health, Articles, Medical specialties, Influenza vaccine, Vaccines, Vaccination, Sanofi, Vaccine, Influenza, Pandemic, Seasonal influenza vaccine brands, H5N1 vaccine

In addition, it will be a key resource to assist against future pandemics," said Paul Hudson, Chief Executive Officer, Sanofi.

Key Points: 
  • In addition, it will be a key resource to assist against future pandemics," said Paul Hudson, Chief Executive Officer, Sanofi.
  • In addition to producing Sanofi's FLUZONE High-Dose Quadrivalent influenza vaccine, this new manufacturing facility will strategically grow Canada's bio-manufacturing sector and install industrial scale capacity to strengthen Canada's preparedness for future pandemics.
  • "With the help of our government partners, bringing this new facility on Canadian soil will increase domestic vaccine manufacturing capacity, strengthen future national pandemic preparedness efforts and bolster worldwide supply of our differentiated influenza vaccines."
  • Following design, construction, testing, and qualification of the facility and equipment, the new Toronto Site facility will be operational by 2026.